Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics and AI-enabled design for RNA therapeutics, announced the launch of its eCOMPASS™ lab-in-the-loop platform, an integrated Design, Make, Test solution for RNA therapeutic development. The platform supports programs across vaccines, CAR-T therapies, gene editing, and protein replacement.

eCOMPASS builds on Eclipsebio's acquisition of Terrain Bio in January 2026, which added AI-enabled RNA sequence design and R&D-scale manufacturing capabilities to the company's established sequencing-based analytics platform, creating a single integrated workflow from design through characterization.

"We built eCOMPASS on deep expertise from nine years of generating the data that defines what makes an effective RNA therapeutic with our support of 80% of the global top 30 biopharma and more than 300 partners across biotech and academia," said Eclipsebio Co-Founder and CEO Peter Chu, Ph.D. "Our partners can now accelerate their programs with a single platform where AI-driven design and deep experimental characterization reinforce each other from day one."

eCOMPASS combines three core capabilities in an iterative loop:

• Design: Eclipsebio's AI optimization platform, eNAVIGATE™, uses machine learning models trained on proprietary experimental datasets to design RNA candidates optimized for expression, stability, and manufacturability.
• Make: Designed sequences advance to rapid prototyping at R&D scale, including linear mRNAs over 10 kb, with QC confirmation of yield and integrity.
• Test: RNA candidates undergo deep sequencing-based characterization through the eMERGE™ platform, generating nucleotide-level measurements of structure, translation dynamics, integrity, and impurities at a resolution beyond standard QC method.

Data from each characterization cycle feeds directly back into eNAVIGATE, so each iteration starts with empirical evidence from over 150,000 data points per target amino acid sequence. In an internal case study developing a gene editing therapy, this approach produced Cas9 mRNA candidates with a 400% increase in protein expression and a 58% increase in editing efficiency, outperforming both industry-standard codon optimization and state-of-the-art foundation models.

"The RNA therapeutics field has lacked a platform that connects sequence design directly to deep mechanistic characterization," said Eckhard Jankowsky, Ph.D., member of Eclipsebio's Scientific Advisory Board and former Vice President of RNA Science at Moderna. "Most programs optimize sequences computationally and then rely on standard QC assays to evaluate the result. This approach misses the nucleotide-level information that is necessary to guide the RNA design towards optimal performance. eCOMPASS closes that gap, generating the nucleotide-level data that enable optimized RNA design."